Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$134.50
-$1.43(-1.02%)
At close: 4:00 PM EST
$134.50
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$88.00 - $196.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.87M
Market Cap
$28.24B
Enterprise Value$19.51K
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)33.7
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,300,000
10 Day Avg. Volume1,749,943
30 Day Avg. Volume1,870,206
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$168.80Price Target Upside25.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)5.23
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationIllumina's trailing-twelve-month operating cash flow (~$1.13B) and free cash flow (~$0.99B) indicate durable internal funding. Persistent FCF supports sustained R&D, scaling NovaSeq X supply, share buybacks and strategic M&A, providing financial flexibility through funding cycles.
Margin Recovery And ExpansionProfitability has meaningfully recovered and management is guiding further expansion (350 bps by end‑2026 ex-acquisitions). Higher gross and operating margins driven by product mix, scale and efficiency improvements enhance durable cash conversion and reinvestment capacity over the medium term.
Installed‑base And NovaSeq X AdoptionRapid NovaSeq X adoption (high share of sequencing volumes) strengthens Illumina's razor‑and‑blades model: a larger installed base drives recurring consumables demand. High throughput supports clinical use cases, deepening competitive moats and durable consumables revenue pull‑through.
Bears Say
Research Consumables WeaknessSustained weakness in research and applied consumables reflects funding uncertainty and cautious lab spending. This structural headwind reduces top‑line growth predictability, increases revenue cyclicality, and limits upside from clinical gains unless research demand normalizes.
Microarrays DeclineA pronounced decline in microarrays reduces product diversification and recurring revenue contributions. Losses tied to large DTC customers highlight customer concentration risks and structural erosion in legacy businesses, increasing dependence on sequencing for durable growth.
Weakened Equity Cushion / Moderate LeverageAlthough leverage has improved versus prior years, materially lower equity reduces the capital‑structure cushion versus historic levels. A thinner equity base constrains strategic optionality, raises vulnerability to shocks, and tempers the safety margin for aggressive buybacks or large scaling investments.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $88.00 and its highest was $196.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $28.24B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.095.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.23.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.15 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 7.133%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$168.80 (25.50% Upside)
$168.80 (25.50% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 789.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$168.80
▲(25.50% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
28.21% Mutual Funds
0.72% Other Institutional Investors
45.63% Public Companies and Individual Investors